Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Essential Drugs List Heralds Price Caps On Hep C Products

This article was originally published in Scrip

Executive Summary

India has announced its national list of essential medicines (NLEM) 2015, which covers a total of 376 drugs across 30 therapeutic segments, including those such as sofosbuvir, pegylated interferon alfa 2a and 2b, raltegravir, trastuzumab, and rituximab, as against 348 medicines across 27 segments listed in NLEM 2011.

You may also be interested in...



Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India

India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.

GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix

GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.

Indegene CTO On Pharma And Blockchain’s Promise Of Better Accountability, Trust

Indegene’s chief technology officer, Tarun Mathur, talks to Scrip about blockchain’s potential in a number of areas across pharma’s operations including the clinical supply chain and trials as well as its role in enabling improved trust in the healthcare data ecosystem.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel